Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DGZU | ISIN: SE0009155518 | Ticker-Symbol: GW3
Frankfurt
21.01.25
09:45 Uhr
1,202 Euro
+0,004
+0,33 %
Branche
Telekom
Aktienmarkt
Sonstige
1-Jahres-Chart
GAPWAVES AB Chart 1 Jahr
5-Tage-Chart
GAPWAVES AB 5-Tage-Chart
GlobeNewswire (Europe)
87 Leser
Artikel bewerten:
(0)

Gapwaves AB: Gapwaves AB (publ) publishes Interim Report for Q2 2024

Finanznachrichten News

Second quarter: 1 April - 30 June 2024

  • Net sales amounted to MSEK 14.5 (8.9), an increase of 62.9% compared to the second quarter of 2023.
  • EBITDA amounted to MSEK -12.5 (-12.9), whereas EBITDA adjusted for results from shares in associated companies amounted to MSEK -8.8 (-9.5).
  • The operating result/EBIT amounted to MSEK -14.3 (-15.0), whereas operating result adjusted for results from shares in associated companies amounted to MSEK -10.6 (-11.6).
  • The result for the period amounted to MSEK -14.4 (-13.8).
  • Earnings per share before and after dilution was neg. (neg.).
  • Cash flow for the period improved and amounted to MSEK -2.2 (-52.4).
  • The Group's cash and cash equivalents amounted to MSEK 66.9 (119.7).

January-June 2024

  • Net sales amounted to MSEK 30.1 (13.8), an increase of 118.1%, compared to the first half of 2023.
  • EBITDA was strengthened compared to the first half of 2023, and amounted to MSEK -25.5 (-29.0), whereas EBITDA adjusted for results from shares in associated companies improved and amounted to MSEK -17.6 (-25.6).
  • The operating result/EBIT amounted to MSEK -29.2 (-33.4), whereas operating result adjusted for results from shares in associated companies amounted to MSEK -21.3 (-30.0).
  • The result for the period amounted to MSEK -28.0 (-31.7).
  • Earnings per share before and after dilution was neg. (neg.).
  • Cash flow for the period amounted to MSEK -22.8 (-65.7).

Significant events during the period

  • The Annual General Meeting of Gapwaves was held on May 3rd, 2024.
  • The Joint Development Agreement (JDA) with Bosch was expanded.
  • Two orders were received from a European Tier 1 supplier, with an order value of 1.9 MSEK and 1.2 MSEK, respectively. A non-binding Letter of Intent (LOI) was signed with the customer.
  • Gapwaves was awarded funding by Vinnova for two research projects, with a value of MSEK 5.2.
  • An order was received from an Asian Tier 1 supplier, with a value of approximately MSEK 5.3.
  • Gapwaves and Sensrad entered into a supply agreement with an expected minimum sales value of approximately MSEK 8.3 for Gapwaves over a three-year period.

CEO Jonas Ehinger comments: "During the quarter, the business continued to strongly develop, in line with how the year began, with strong order intake and increasing sales. We are scaling up and delivering according to our customer agreements. I would like to emphasize the importance of the fact that an increasing number of antennas that we have developed are being put into production and serial deliveries are starting."

The full report is available as attached PDF and on the company's website https://www.gapwaves.com/investors/financial-reports-and-documents/

Online presentations

Gapwaves CEO Jonas Ehinger will hold two presentations today, August 22nd, regarding the second quarter.

The first presentation will begin at 10:00 a.m. (CEST), followed by a Q&A session moderated by G&W Fondkommission. The presentation and Q&A session will be held in Swedish. To participate, please register via this link at the latest today at 9:30 am: https://events.teams.microsoft.com/event/bf9478a7-ae61-470d-9102-eb39f0919649@6137c0b0-f16e-4ae1-ba3a-7fcede0c24a7

The second presentation will start at 11:00 a.m. (CEST). It will be followed by a Q&A session moderated by Redeye's analyst Rasmus Jacobsson. The presentation and Q&A session will be held in English. It can be accessed via this link: https://www.redeye.se/events/1018249/live-q-gapwaves. A recording of the presentation will be available afterwards.

For more information, please visit www.gapwaves.com or contact:
Jonas Ehinger, CEO?Gapwaves?AB?(publ)
Phone number:?+46?733 44 01 52
E-mail:?jonas.ehinger@gapwaves.com

Robert Berhof, CFO?Gapwaves AB (publ)
Phone number: +46 706 00 59 07?
E-mail:?robert.berhof@gapwaves.com?

Gapwaves?Certified Adviser is G&W?Fondkommission?AB?
www.gwkapital.se

About Gapwaves AB (publ)
Gapwaves AB (publ) originates from research conducted at Chalmers University of Technology and was founded in 2011. Gapwaves' vision is to be the most innovative provider of mm-wave antenna systems and the preferred partner to those pioneering next generation wireless technology for a safer and more sustainable society. By leveraging the disruptive Gapwaves technology, we help pioneers in automotive and telecom to create highly efficient mm-wave antenna systems that contributes to re-defining everyday life.
Gapwaves' share (GAPW B) is traded on the Nasdaq First North Growth Market Stockholm with G&W Fondkommission as certified adviser.

This information is information that Gapwaves is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-22 07:00 CEST.

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.